James Fang
Cardiovascular Disease · Salt Lake City, UTNPI 1447217740
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,794 of the $67,174 with a category attached, or 66.7%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2019 at $50,830 and has fallen 85.8% since, to $7,213 in 2025. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $959.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Astrazeneca UK Limited$14K
- Novartis$11K
- Acorda Therapeutics, Inc$10K
- Sanofi US Services Inc.$7K
- Boston Scientific$4K
- plus $5K from 11 others
Across 37 payments — averaging $4953.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$94K
- Ortho-clinical Diagnostics, Inc.$56K
- Quidel Corporation$32K
- Currax Pharmaceuticals LLC$1K
What the payments were for
- Consulting fees$44,79467%
- Speaking & faculty fees$2,5004%
- Travel & lodging$17,46926%
- Food & beverage$2,4114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $15,512 |
| Astrazeneca UK Limited | 8 | $13,848 |
| Novartis | 5 | $11,119 |
| Acorda Therapeutics, Inc | 8 | $10,197 |
| Sanofi US Services Inc. | 6 | $7,000 |
| Boston Scientific | 9 | $4,140 |
| ZOLL Respicardia, Inc. | 2 | $3,109 |
| Quidel Corporation | 1 | $1,350 |
| Biotronik Inc. | 2 | $327 |
| Heartflow, Inc. | 1 | $141 |
| Paragonix Technologies, Inc. | 1 | $138 |
| Abbott | 2 | $130 |
| Abiomed | 1 | $62 |
| Medtronic | 1 | $39 |
| Pfizer | 1 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Romark Laboratories, LC | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$14,101
- FARXIGA$13,599
- ENTRESTO$10,296
- GENERAL - THERAPIES$3,988
- remede System$3,109
- Orsiro Mission$327
- FFRct$141
- SherpaPak$138
- LIVERguard$138
- LUNGguard$138
- BaroGuard$138
- PancreasPak$138
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$116
How this compares
$67,174 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 16 | $16,497 |
| EliquisApixaban | 12 | $12,505 |
| JardianceEmpagliflozin | 14 | $12,382 |
| Spironolactone | 36 | $401 |
| Metoprolol Succinate | 26 | $290 |
| Atorvastatin Calcium | 31 | $240 |
| Rosuvastatin Calcium | 13 | $168 |
| Lisinopril | 13 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $11,119 | $16,49716 claims |
| PfizerEliquis | $35 | $12,50512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Salt Lake City
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Jeffrey OsbornSalt Lake City$69K
- Hannah RaaschSalt Lake City$62K
- Benjamin PetersonSalt Lake City$39K
- Jeffrey AndersonSalt Lake City$19K
- Mehmet AkkayaSalt Lake City$18K
- Ashley GoodwinSalt Lake City$17K
- Edward GilbertSalt Lake City$16K
- Damian DomanskiSalt Lake City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.